

Cover Story
Free
By Paul Goldberg and Matthew Bin Han Ong
A foundation established by Silicon Valley entrepreneur Sean Parker—founder of Napster and first president of Facebook—has committed $250 million to research in cancer immunotherapy.
In Brief


Drugs & Targets
Trending Stories
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- Pam Bondi diagnosed with thyroid cancer
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer











